PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Feng Qian

HEDS Regional Team, Merck & Co., Inc., Rahway, NJ, USA.

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs1 Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

AUG 7, 2026 · JOURNAL ARTICLE

Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland.

Journal of Medical Economics

A rigorous health economic analysis based on a pivotal Phase 3 RCT (KEYNOTE-689) with clear cost-effectiveness results well below the Swiss willingness-to-pay threshold, though grounded in modelling rather than direct trial cost outcomes.

Strong EvidenceDzhumber Ugrekhelidze Neoplasm Staging Head and Neck Neoplasms

Reported

Life expectancy extension1.81 years

Incremental QALYs1.42

ICER (cost per QALY gained)CHF 14,227/QALY gained

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support